First FDA-Approved Treatment for MacTel Performed

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the first commercial manufacturing, shipment, and surgical procedure for ENCELTOTM (revakinagene taroretcel-lwey), an encapsulated cell-based gene therapy and the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). “This is a huge milestone for people living with MacTe